AU619291B2

AU619291B2 – Lymphographic imaging method and kit
– Google Patents

AU619291B2 – Lymphographic imaging method and kit
– Google Patents
Lymphographic imaging method and kit

Download PDF
Info

Publication number
AU619291B2

AU619291B2
AU34959/89A
AU3495989A
AU619291B2
AU 619291 B2
AU619291 B2
AU 619291B2
AU 34959/89 A
AU34959/89 A
AU 34959/89A
AU 3495989 A
AU3495989 A
AU 3495989A
AU 619291 B2
AU619291 B2
AU 619291B2
Authority
AU
Australia
Prior art keywords
antibody
imaging
agent
magnetic resonance
organ
Prior art date
1985-07-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU34959/89A
Other versions

AU3495989A
(en

Inventor
Milton David Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Immunomedics Inc

Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1985-07-05
Filing date
1989-05-18
Publication date
1992-01-23

1989-05-18
Application filed by Immunomedics Inc
filed
Critical
Immunomedics Inc

1989-09-14
Publication of AU3495989A
publication
Critical
patent/AU3495989A/en

1992-01-23
Application granted
granted
Critical

1992-01-23
Publication of AU619291B2
publication
Critical
patent/AU619291B2/en

2006-07-03
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K49/00—Preparations for testing in vivo

A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations

A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier

A61K49/10—Organic compounds

A61K49/14—Peptides, e.g. proteins

A61K49/16—Antibodies; Immunoglobulins; Fragments thereof

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo

A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus

A61K51/04—Organic compounds

A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins

A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody

B—PERFORMING OPERATIONS; TRANSPORTING

B82—NANOTECHNOLOGY

B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

G—PHYSICS

G01—MEASURING; TESTING

G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES

G01R33/00—Arrangements or instruments for measuring magnetic variables

G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance

G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]

G01R33/48—NMR imaging systems

G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console

G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution

G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61B—DIAGNOSIS; SURGERY; IDENTIFICATION

A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment

A61B6/42—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment with arrangements for detecting radiation specially adapted for radiation diagnosis

A61B6/4208—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment with arrangements for detecting radiation specially adapted for radiation diagnosis characterised by using a particular type of detector

A61B6/4258—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment with arrangements for detecting radiation specially adapted for radiation diagnosis characterised by using a particular type of detector for detecting non x-ray radiation, e.g. gamma radiation

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K2123/00—Preparations for testing in vivo

Abstract

An improved method for lymphoscintigraphy or magnetic resonance lymphography involves subtraction of a negative image produced using a gross imaging agent from a positive image produced with a specific antibody imaging agent. Another embodiment of the invention uses an antibody to lymphatic tissue as an imaging agent for lymphatics. A further embodiment uses a magnetic resonance image enhancing agent for magnetic resonance lymphography.Reagents and kits for use in the foregoing method are also provided.

Description

S- 619291 COMMONWEALTH OF AUSTRALIA Patent Act 1952 CO M P L E T E S P E C I F I C A T ION
(ORIGINAL)
Class Int. Class Application Number Lodged S’ Complete Specification Lodged Accepted Published Priority: t Related Art Name of Applicant N-DAV-I-D-G&DBRG.
Address of Applicant -11 DenmanGou t- ho–H New J.e-seyr -Uni-ted–St-at-es-Gf Amer-ie-a ,4 Actual Inventor MILTON DAVID GOLDENBERG Address for Service F.B. RICE CO., Patent Attorneys, 28A Montague Street, BALMAIN. 2041.
Complete Specification for the invention entitled: “LYMPHOGRAPHIC IMAGING METHOD AND KIT” The following statement is a full description of this invention including the best method of performing it known to Me:- BACKGROUND OF THE INVENTION The present invention relates to a method for imaging lymphatic structures and to a kit suitable for use therefor.
There is a need, particularly in oncology, for a method that clearly delineates lymphatic structures.
Lymphatic structures, particularly lymph nodes, drain *o tissue and ectravascular regions of various molecular and macromolecular substances, including antigens, \O infectious agents, and cells, serving as a filter as o-o well as a part of the host organism’s immunological apparatus. It is well known that certain substances with appropriate physical properties, when injected into a suitable tissue plane, are transported from the injection site by a drainage system and sequestered in regional and then more distant lymph nodes. Some of o these substances, particularly colloids, are passively o o retained in sinusoids and actively phagocytosed by the io o reticuloendothelial (RE) cells within the lymph node.
.0O When a radioisotope is incorporated in such a pharmaceutical suitable for lymphatic accretion, the lymph system, particularly the draining lymph nodes, can be imaged with a suitable scintigraphic system.
However, when a disease process impacts upon these lymphatic structures, the image of the lymph S nodes may be affected in such a manner that their form and appearance is different. For example, a cancer infiltrating a lymph node may replace a large enough portion of the RE tissue in the node to exclude an imaging agent, a radiocolloid, from that area of the node, resulting in a “negative” image effect.
Similar results may be obtained when the lymph node structure and function is compromised by infectious agents, bacteria, fungi, parasites and viruses.
r la -e However, the use of such lymphoscintigraphic methods can present problems in diagnostic interpretation, since “absent” lymph nodes or “decreased uptake of radioactivity” are not in themselves diagnostic of neoplastic or other involvement of the lymph nodes. Moreover, there may be lymph nodes that appear normal in the lymphoscintigram, or even show increased radiocolloid uptake, when these nodes are found to have metastases upon microscopic examination. Conversely, nodes with no apparent metastatic involvement may show decreased or no radiocolloid uptake. Thus, a method with greater specificity for lymph node involvement in cancer or in infectious diseases would be of considerable diagnostic value.
Methods of localization and therapy of tumors and infectious lesions using labeled antibodies and antibody fragments which specifically bind markers produced by or associated with tumors or infectious lesions have been disclosed, inter alia, in Hansen et al., S U.S. Patent 3,927,193 and Goldenberg, U.S. Patents 4,331,647, 4,348,376, 4,361,544, 4,468,457, 4,444,744, 4,460,459 and 4,460,561, and in related pending applications Australian application numbers 24931/84 and 31296/84, the disclosures of all of which are incorporated herein in their entireties by reference. See also DeLand et al., J. Nucl. Med., 20. 1243-50(1979).
These methods use radiolabeled antibodies which specifically bind to markers produced by or associated with tumors or infectious lesions, and result in a “positive” image, uptake of radioactivity attached to the antibody in the structure involved with tumor or infectious lesion and having the appropriate antibody target, thus permitting a visualization of the involved structure. Further improvements in the specificity and resolution of these methods is achieved by use of various subtraction techniques which are also disclosed in the aforementioned references, and which enable background, non-specific radioactivity to be distinguished from specific uptake by the tumor or lesion.
Others have employed lymphoscintigraphy to study various types of cancers, using various imaging agents. Current lymphoscintigraphic methods employ Tc-99m antimony sulfide colloid (Tc-ASC) as the imaging agent of choice, although Tc-99m stannous phytate has also been reported as useful. See, Ege et al., Brit. J. Radiol., 52, 124-9(1979); and Kaplan et al., J. Nucl. Med., 20, 933-7(1979).
2 1– Earlier, Au-198 colloid was used, as reported by, Hultborn et al., Acta Radiol., 43, 52(1955); Turner-Warwick, Brit. J. Surg., 46, 574(1959); Vendrell-Torne et al., J. Nucl. Med., 13, 801(1972); Robinson et al., Surg. Forum, 28, 147(1977); Sherman et al., Am. J. Roentgenol., 64, 75(1950); and Rosse et al., Minerva Med., 57, i151(1966). Intraperitoneal autologous Tc-99m-labeled erythrocytes were used in mediastinal lymphoscintigraphy to study ovarian cancer \0 by Kaplan et al., Br. J. Radiol., 54, 126(1981).
Tc-99m-labeled liposomes were used in axillary lymphoscintigraphy of breast cancer by Osborne et al., Int. J. Nucl. Med. Biol., 6, 75(1979). Tc-99m rhenium sulfide colloid was used in breast cancer lymphoscintigraphy by Gabelle et al., Nouv. Presse Med., 3067(1981). The use of Tc-ASC for lymphoscintigraphic imaging of mammary and prostatic cancers, as well as for malignant melanoma, has been reported by, e.g., Ege, Sem. Nucl. Med., 13, 26(11983); Ege, J. Urol., 20 127, 265-9 (1982); and Sullivan et al., Am. J.
Radiol., 137, 847-51(1981).
a9 DeLand et al. Cancer Res., 40, 2997-3001 (1980), disclose a scintigraphic imaging method using anti-carcinoembryonic antigen antibodies labeled with 1-131. They found that the tumor marker, carcinoembryonic antiger (CEA), was accumulated in lymph node metastases and also in some non-metastatic lymph nodes in the drainage path of proximal tumors, and was revea.led by binding to labeled antibody.
0 Lymph nodes have been imaged by magnetic resonance imaging techniques, but not with the use of image enhancing contrast agents, and not with antibody-conjugated imaging agents.
It is important in certain clinical situations to detect the presence or absence of a particular organ, such as the ovary. Moreover, it is often necessary to determine whether an organ is anatomically correct and whether it has pathology, obstruction, infection, neoplasia and the like, by a non-invasive technique. It would be desirable to have an organ, imaging method using organ-specific imaging agents that would make it possible to obtain a “positive” image of the organ, when normal,and a dr ,ct in organ visualization if pathology is present. Such a method would provide a new apprcach to scintigraphic and magnetic resonance imaging of organs and tissues in the body based upon their immunological specificity.
4 Antibody conjugates comprising organ-specific and tissue-specific antibodies and addends for scintigraphic detection or magnetic resonance image enhancement have not been used as organ imaging reagents.
A need continues to exist for lymphographic imaging methods which are more sensitive and specific for tumor and infectious lesion involvement in lymphatic structures, and for organ imaging reagents and methods with high specificity for differentiation of particular organs and tissues from surrounding structures.
SUMMARY OF THE INVENTION In a first aspect the present invention consists in a Slymphographic imaging method for imaging of a tumor or infectious lesion or a localized product thereof in a S 15 mammalian lymphatic structure, comprising the steps of: parenterally injecting a mammalian subject, at a locus and by a route providing access to said lymphatic structure, with an amount of a gross lymphoscintigraphic imaging agent or lymphomagnetic resonance image enhancing agent sufficient to permit a scintigraphic image or an S’ enhanced magnetic resonance image of said structure to be effected; and obtaining a gross positive scintigraphic image or a gross positive enhanced magnetic resonance image of said 25 structure, at a time after injection of said agent sufficient for said agent to diffusely accrete in said structure, wherein said gross imaging agent comprises an antibody or antibody fragment which specifically binds to normal lymphatic cells or tissues, said antibody or antibody fragment being labelled with a radioisotope or a magnetic resonance image enhancing agent; and wherein a tumor or infectious lesion or a localized product thereof in said structure is revealed as a negative image.
i..e ~-t=e~Zi-JI~ I ~-V~UI -YI-9PI 5 In a second aspect the present invention consists in a method of organ imaging in a mammalian subject by scintigraphy or magnetic resonance imaging, comprising the steps of: parenterally injecting a mammalian subject, at a locus and by a route providing access to an organ of interest, with an antibody or antibody fragment which specifically binds a marker produced by or associated with said organ, said antibody or antibody fragment being labelled with a radioisotope capable of external detection or with a magnetic resonance image enhancing agent, the o oo amount of the labelled antibody or antibody fragment being o sufficient to permit a scintigraphic image or an enhanced Smagnetic resonance image of said organ to be obtained; and obtaining a positive scintigraphic or a positive a aenhanced magnetic resonance image of said organ, at a time after injection of said agent sufficient for said agent to diffusely accrete in said organ and specifically bind to said marker.
In a third aspect the present invention consists in a 8 oo lymphographic imaging kit when used in the lymphographic *o imaging method of claim i, comprising: a gross imaging agent comprising an antibody/ fragment which specifically binds to normal lymphatic 25 cells or tissues, said antibody/fragment being lcLbelled with a radioisotope or a magnetic resonance enhancing o agent; and a sterile, pharmaceutically acceptable injection vehicle.
6 In a fourth aspect the present invention consists in an organ imaging kit when used in the method of claim 4, comprising: an antibody or antibody fragment which specifically binds a marker produced by or associated with an organ, the antibody or antibody fragment being labelled with a radioisotope capable of external detection or with a magnetic resonance imaging enhancing agent; and a sterile, pharmaceutically acceptable injection vehicle.
AteA
II,
Au IA AC I Y.I
~.I
method of lymphographic imaging wherein an mage is taken using a labeled specific an fragment as a gross imaging agent, and a mage is taken after specific uptake gen and clearance of nonspecifically bpa ntibody has occurred, the former image gsubtracted from the latter to refine its Reagents and kits useful for practicing the methods of the invention are also provided.
DETAILED DISCUSSION In one methodological aspect, the present invention combines two approaches hitherto employed separately, in a way which has not been suggested in the earlier work on either technique. The work of DeLand, in collaboration with the present inventor, was related to localization of radiolabeled antibodies in tumors or accreted antigen foci of the lymphatics.
The work of others was related to lymphoscintigraphic D imaging of lymphatics with gross imaging agents. The present invention relates to the hitherto unsuggested S’ correlation and computer processing of these two images to refine the positive image of a tumor or other pathological lesion, or accreted antigen focus, I revealed by specific antigen-antibody binding.
The lymphographic method of -the invention can be practiced either with scintigraphio or magnetic iresonance imaging agents. A combination of these imaging agents can also be used, although this (0 requires more complex instrumentation and data processing and may therefore be impractical in most cases. The subtraction of images can be readily achieved using conventional software. The imaging methods of DeLtnd et al., Cancer Res., 40, 3046(1980), are illustrative of the computerized subtraction methods known ir the art.
Major areas of interest for lymphography include regional spread of nooplastic and infoctious lesions of the breast, colon and rectum, prostate, ovary and testes. Major lymph nodes involved in these various lesions include axillary and internal mammary nodes- in the chest, and the pararectal, anterior pelvi I (obturator), internal iliac (hypogastric), presacral, external and common iliac, and para-aortic nodes.
7 Thus, applications where lymphographic imaging would be useful include, but are not limited to, pathological lesions affecting the major organs of the chest, abdomen and pelvis, as well as the skin, from which the regional and, subsequently, more distant lymphatics can be involved.
Scintigraphic imaging according to the method of the invention is effected by obtaining a scintigram of the lymphatic structure of interest, using as an \O imaging agent a radiolabeled antibody which specifically binds to a marker produced by or associated with a tumor or infectious lesion located in the structure or at a ,ocus proximal to the structure and draining into the structure, such that the antigen/marker accretes in discrete foci therein; also obtaining a scintigram of the structure using a gross imaging agent which is a radiolabeled material which accretes in the structure but which does not specifically bind to the tumor or lesion, or to an accreted antibody 0) focus; and subtracting the latter image from the former to produce a refined positive image of the site I “P or sites of localization of the labeled specific *antibody within the structure.
It will be appreciated that a specific labeled antibody/fragment imaging agent can function as a gross imaging agent for early imaging of a structure, when it is diffusely accreted therein, and still So function at a later time as a specific imaging agent 4 once clearance from organ background and localiza- Z tion/specific antigen-antibody binding at the site or 4 sites of specific uptake by tumor, lesion or discrete antigen focus has occurred. This forms the basis for another embodiment of the present method.
The “gross” labeled imaging agent used to obtain the latter scintigram may be a radiocolloid-type agent t t which is scavenged by the reticuloendothelial system (RES) and accretes in lymphatic structures. It may, also be a radiolabeled liposome or a radiolabeled agent such as gallium citrate, labeled bloomycin, or \l the like, which accretes in lymphatics. Finally, and advantageously for certain cases, it may be a new type of gross imaging agent developed especially for this invention, namely, a radiolabeled antibody which specifically binds to normal lymphatic tissues or cells, but not to tumors or lesions located therein or proximal to and draining into the structure, so that it is also diffusely distributed in the lymph nodes and reveals the internal structure thereof.
8 Examples of gross scintigraphic imaging agents include but are not limited to radiocolloids, e.g., Tc-ASC, Tc-99 sulfur colloid, Tc-99 stannous phytate, Au-198 colloid, Hg-197 sulfide colloid, In-111 phosphate colloid and the like, as well as the other types of agents reported in the literature, representative examples of which are disclosed hereinabove. Other colloidal preparations using radionuclides other than Tc or Au can be used, e.g., \O colloidal In-111, Ru-97, Ga-67, and the like, or colloids incorporating 1-131 or 1-123. Such preparations are conventional and well known to the ordinary skilled artisan in this field. See, e.g., Rayudu, “Radiotracers for Medical Applica- tions, Vol.
I” (CRC Press, Boca Raton, Fla., 1983).
Radiolabeled antibodies to markers characteristic of lymphatic tissue are a new kind of gross imaging agent which are also useful in the method of the present invention. They are an example of an O2 immunologic, organ-specific imaging agent which can be used to ascerta’n the location and shape of a specific organ and reveal possible abnormalities therein. Such agents are useful for imaging organs other than lymphatics, liver, spleen, pancreas, and the like, and many antibodies which specifically bind to tissues of these organs are known and/or under current investigation and development.
Organ-associated and organ-specific antibodies can be developed by immunizing’ a suitable animal host S0 with certain mammalian tumors or normal organ/tissue extracts and/or cells. It is well known that use of tumors as immunogens can result in antibodies which not only react with neoplasia but also with normal tissue components which sometimes show an organrestricted nature. Histogenetic and functional differences between various tissues and organs of the body of course suggest that distinct antigens are present and identifiable. A body of scientific literature already exists which claims the identi- SO\ fication of organ-specific antigens, either using classical immunization approaches or by immunizing with specific tumors, and this is reviewed by Goldenberg et al., Cancer Res., 36, 3455(1976), showing that such antigens are known and available.
9 Similar orean- and tissue-associated and specific antigens are identifiable by hybridoma methods which produce monoclonal antibodies. One recent development is the production of human hybridoma monoclonal antibodies by securing lymphocytes or plasma cells from patients showing certain organ-restricted autoimmune diseases, thyroiditis, gastritis, ulcerative colitis, myositis, and the like. These antibody-producing cells are then fused \0 in vitro with human or murine myeloma cells and hybridomas of appropriate anti-organ and anti-tissue antibody formation are produced and propagated, using well known methods. Also, patients with specific tumor types can be used as a source of such lymphocytes or plasma cells, or such patients can be further immunized with such tumor cells for stimulating the production of anti-organ and anti-tissue antibodies.
Thelymphatic tissue removed is then used for fusion Swith suitable myeloma cells, by procedures which are S’ 30O by now well known and conventional in the art.
Organ-associated and organ-specific antigens can be isolated for immunization of another species, e.g., sub-human primates, rodents, rabbits, goats, etc., by a nUmber of methods known in the art, such as isolation of cell membranes or disruption of the j ,o cells, by oentrifugation, sonication, etc., to Sbtain intracellular antigens. It is preferable, for ,F *these purposes, to use intracellular as opposed to surface and extracellular antigens. In this manner, organ-associated and organ-specific antigens can be obtained from a large number of tissues and organs of the body, including brain, thyroid, parathyroid, larynx, salivary glands, esophagus, bronchus and lungs, heart, liver, pancreas, stomach and intestines, kidney, adrenal gland, ovary, testis, uterus, prostate, etc. Of furtler interest is the differentiation of different tissue and cellular components within an organ, such as tubular and glomerular kidney, different regions and cell types 6f V\0 the brain, endocrine and exocrine pancreas, etc., especially by the identification of antigons and antigen opitopos restricted to the individual cell and tissue types in question, as accomplished with polyclonal and/or hybridoma-monoclonal antibody-production methods known in the art.
10 Examples of antibodies which specifically bind to lymphatic cells and/or tissues, and which are useful as gross imaging agents when labeled with a radioisotope or magnetic resonance image enhancing agent, include the T101 rnurine monoclonal anti-T-cell antibody reported by Royston et al. Blood, 54(Suppl.
1) 106a(1979); and the T200 anti-lymphoreticular cell monoclonal antibody whose specificity was reported by Hsu et Am. J. Pathol. 1 141, 387 IC (1984). Other antibodies to T-cells and B-cells, which can also be used for such agents, include, e.g., the B32 and BAl anti-B-cell monoclonal antibodies reported in Hsu et al. Am. J. Olin. Pathol, 80, 415 (1983 and in Hsu et al, Am J Pathol, 114 387 (1984); the 0KT10, AIG3, l-ILA-DR and Lou 10 monoclonals reported in Hsu et al., Ibid.; and anti -lymphocyte monoclonals reported by Foon et Blood, 60, 1 (1982), LeBlen et al., J. Immunol., 125, 2208(1980), and Beverl.ey et al. Eut’. J. Immunol,, 1 329(1981) 120 The antibody may be whole IgG, IgA, IgD, IgE# IgM or a fragmenu such as, I(ab’)2, F(ab)2, Fab’, Fab or the like, including iso-types and subtypes thereof. It can be a polyc,ona. antibody, preferably if an affinity-purified atitibody from a human or an appropriate animal, a igoat, rabbit, mou~se or the like, or a monoclonal antibody prepared by converitioQnaI techniques, a murine antibody derived K from a hybridoma produced by fusion of lymph or spleen i cells from a mouse immunized against a lymphatic system antigen- with myeloma cells from an appropriate immortal cell line.
It should be noted that mixtures of antibodies, isotypes, and immunoglobulin classes, including fragments, can be used, as can hybrid antibodies and/or antibody. fragments. In particular, hybrids having both T101 and T2?00 specificities, or hybrids having anti-T-cell and anti-B-cell specificities, may \0 be particularly useful as gross -lymphatic imaging agents, both for scintigraphy and for magnetic resonance lymphography, depending upon the label or enhancing moiety conjugated thereto. Hybrid antibody fragments with dual specificities can be prepared analogously to the anti-tumor marker hybrids disclosed in U.S. Patent 4,361,544. Other techniques for preparing hybrid antibodies are disclosed in, e.g., US. Patents 4,474,893 and 4,479,895, and in Milstein et al., Immunol. Today, 5, 299(1984).
4, I, 4′ 4 4 .440 4 4 0 00 4 4 04 4 0 4 4 44 4 ti 44 4 ‘0 44 230 The antibody/fragment used for the specific imaging agent can be any of the antibodies which bind to tumor-specific and/or tumor/associated markers such as those disclosee in the herein referenced U.S.
Patents and Patent Applications, including hybrid antibodies and/or fragments, as well as others which are known to the ordinary skilled artisan in this field, antibodies which bind to human T-cell l. mphoma viruses (HTLV), and those which arc yet to be discovered. Also useful are antibodies to markers 2Q produced by or associated with infectious lesions of the lymphatic system, or lesions located proximal to and draining into lymph nodes. Lymphotropic microorganisms include bacteria, viruses, parasites, and the like which show a predilection for sojourn in and ihvolvement of lymphatic structures in the body.
Among the viruses, the HTLV family have a predilection for T-lymphocytes, and are involved in leukamias, lymphomas, and AIDS. The HTLV form considered etio.logic for AIDS is HTLV-III. Cytomegalovirus, EB herpes virus, and the like, also show some predilection for lymphatic structures although the site of primary infection can be other tissues, with subsequent involvement of lymphatic tissues. Howrver, virtually all pathogenic microoorganisms can demonstrate involvement of lymphatic tissues during passage and infection in the body.
12 I- 11 Examples of antibodies to infectious organisms and/or antigens produced by or accreted by or in the vicinity of infectious lesions include, antibodies against variola virus, yellow fever virus, arboviruses, herpes viruses, myxoviruses, enteroviruses, rabies virus, hepatitis A and B viruses, Chlamydia psittaci, Rickettsia prowazeki and other rickettsia, lymphocytic choriomeningitis virus, Neisseria meningitidis, Neisseria gonorrhoeae, \O Corynebacterium diphtheriae, Clostridium tetani, Bacillus anthracis, Yersinia pestis, Vibrio cholerae, salmonella and shigella bacterial species, staphylococci species, Reponema pallidum, leptospiral species, Mybobacterium leprae, Mycobacterium tuberculosis, Histoplasma capsulatum, Coccidioides immitis, various streptococci, Plasmodium falciparum and other plasmodia, Toxoplasma gondii, Leishmania donovani, various trypanosomes, Entameba histolytica, Giardia lambia, Trichinella spiralis, Strongyloides stero coralis, Antiostrongylus cantonensis, Wucheria bancrofti, Schistosoma mansoni and other schistosomal helminths, Paragonimus westermani, echinococcal species, and the like. Listings of representative disease-causing infectious organisms to which antibodies can be developed for use in this invention are contained in the second and subsequent editions of Davis et al, “Microbiology” (Harper Row, New York, 1973 and later), and are well known to the ordinary skilled art worker.
to 0 tO 4 1 4 0 4 aa 4440 94 0 64 4 64 4 t a *44* 4 44
SO
I
9* 4 04 7 0> Again, the antibody may be whole IgG, IgA, IgD, IgE, IgM or a fragment such as, F(ab’)2, F(ab)2, Fab’, Fab or the like, including isotypes and subtypes thereof. It can be a polyclonal or a monoclonal antibody/fragment, a mixture of antibodies/fragments or a hybrid. Here, where the image is produced as a result of specific antibody-antigen binding rather than non-specific uptake by the RES, it may be especially advantageous to use antibody fragments which do not have the Fo portion.
og The radiolabel for both types of scintigraphic imaging agents is preferably an isotope with an energy in “the range of 50-500 Kovey. Whore more than one isotope is used for simultaneous subtraction, the two labels should be of sufficiently different energies -to be separately detectable with a gamma camera having a collimator with the appropriate characteristic, Many of the preferred radiocolloids are available commercially or can be prepared according to conventional methods reported in the literature, including the illustrative references hereinabove. Colloids having a particular range of particle size are optimal for interstitial administration and subsequent uptake by the lymphatic system draining into lymph nodes of interest. A particle size of less than 25 nm, e.g. 0.1 25 nm, preferably 1 -20 nm, is preferred for optimal mobilization. Control of the particle size as a function of the gelling conditions for the colloid is conventional in the art and can be done without undue experimentation by the skilled artisan, Commercial colloids are available with acceptable partical sizes, 198-Au colloid with a particle size of 2-10 nm, 99m-Ti sulphide colloid with a high but nevertheless usable particle size over 100 nm, and 197-Hg sulphide colloid with a particle size of 10-150 nm. 99m-Tc stannous phytate is ionic, and 51-Cr and 99m-Tc human serum albumin .i are proteinaceous with mw 60,000.
Ott The alternative type of gross imaging agent disclosed S hereinabove, an antibody to a marker associated with lymphatic tissue, can be prepared by known methods, if existing antibodies are considered unsuitable or if different or more discriminating specificities are desired. Generally, whole lymph cells, tissue samples and/or cell or tissue fractiors, membranes, antigen extracts or purified surface antigens are used to challenge the immune system of a suitable animal, a mouse, rabbit, hamster, goat or the like, the antigen being rendered immunogenic by aggregation if necessary and/or by coadministration with a suitable conventional adjuvant, Hyperimmune antiserum can be isolated and polyclonal antibodies prepared by conventional adjuvant. Hyperimmune antiserum can be isolated a- polyclonal antibodies prepared by conventional procedures. Alternatively, spleen cells can be fused with immortal myeloma cells to form hybridoma cells producing monoclonal antibodies, by what are now conventional procedures. See, the procedures in the above-referenced U.S. Patent Application Serial No. 609,607 for illustrative techniques. Hybridomas using animal, mouse, or human myeloma cell lines and animal or human sple n or lymph cells are all known in the art, and can be made and used for the present method. See, for example, Glassy et al., “Human Monoclonal Antibodies to Human Cancers”, in “Monoclonal Antibodies and Cancer”, Boss et al., Eds., 163-170 (Academic Press, 14 I- 1983). The specific antisera or monoclonals are screened for specificity by methods used to screen the anti-lymphocyte clones in the references cited hereinabove, which methods are also conventional by now in this art.
In an alternative embodiment of this approach, the gross agent can be a labeled antibody to a marker associated with a lymphatic structure, lymphatic tissues or lymphocytes, wherein the antibody also 1O specifically binds to a marker produced by or associated with liver and/or spleen tissues or components.
Among the anti-lymphatic clones disclosed hereinabove, at least the anti-T101 antibody is also cross-reactive with spleen. Antibodies which are cross-reactive with both lymphatic tissue/cells and liver and/or spleen cells/tissue can also be prepared by well-known hybrid antibody production techniques, such as those r.o disclosed in the above-referenced U.S. 4,331,647, 4,474,893 and 4,479,895. These would combina 20 anti-lymph tissue antibodies with antibodies which B specifically bind to liver and/or spleen.
OS 9 *.oo Such antibodies can be produced using liver cells isolated from normal liver tissue obtained at o” autopsy. For example, mice can be immunized with such tissues for a period necessary to evoke anti-liver antibodies. The spleens of these mice are removed and then fused, by standard methods, with a murine myeloma cell line suitable for hybridoma production. Using a e methods already standard in the art, monoclonal anti- *o 0 body-producing hybridomas are selected and propagated, and those with liver-restricted or liver-associated antibody production are cloned and expanded as a source of liver organ antibodies.
Similar approaches can be used with human tumors or other normal human tissues for the production of antibodies that are organ-associated or tissuespecific. Absolute tissue specificity is not required since significant quantitative differences ordinarily suffice for operational specificity for imaging \O purposes.
It will also be appreciated that the anti-liver antibodies can be used as a liver background subtraction agent when visualizing tumors in the liver.
These tumors can be of non-liver origin or of liver origin. Even if a tumor of liver origin has the liver organ-associated antigen, subtraction of the latter 15 can be accomplished without missing the tumor if another liver -cancer-associated antigen is used as the target for the specific anti-liver cancer antibody.
For example, antibody against alpha-fetoprotein (AFP) can be used in combination with an antibody against normal liver organ antigen, thus refining the image of areas containing AFP in the liver.
The antibodies can be radiolabeled by a variety of methods known in the art. Many of these methods %O are disclosed in the above-referenced U.S. Patents and Patent Applications, and include direct radioiodination, chelate conjugation, direct metallation, and the like. See also, Rayudu, op. cit.; and Childs et al., J. Nuc. Med., 26, 293(1985). Any conventional method of radiolabeling which is suitable for labeling isotopes for in vivo use will be generally suitable for labeling imaging agents according to the present invention.
The gross imaging agent will normally be ;QO administered at a site and by means that insure that it is mobilized and taken up into the lymphatic circulation. This will vary with the system to be imaged. Multiple injection sites may be preferable in order to permit proper drainage to the regional lymph nodes under investigation. In some cases, injections around the circumference of a tumor or biopsy site is desired. In other cases, injection into a particular sheath or fossa is preferred. Injection into the webs of the fingers or toes is a common mode used to study *s 30 peripheral lymphatics.
SFor example, for visualization of the internal mammary lymphatics in breast cancer with Tc-ASC, the radiocolloid is injected into the posterior rectus sheath at the insertion of the diaphragm in the subcostal site, using about 0.5 mCi of radiocolloid in a volume usually not exceeding about 0.3 ml. This method can also be used to visualize iliopelvic lymphatics in genitourinary cancers. In patients with breast carcinoma, a unilateral injection is made in AO the subcostal site ipsilateral to the tumor, and then repeated later on the contralateral side to observe cross drainage between the ipsilateral and contralateral nodes. Imaging is effected at appropriate times after each injection and injection of the specific imaging agent is coordinated with the injections of the gross imaging agent to permit optimal visualization of the positive and negative images.
16 Images of axillary, subclavian and supraclavicular nodes may be obtained by injecting the imaging reagents into the medial surface of the upper arms (ipsilateral and contralateral) of patients with breast cancer.
Another approach is to inject about 0.1 mCi of Tc-ASC around the areola tissue of the breasts bilaterally, and then image the axilla. In addition to periareolar injection, interdigital administration \O of radiocolloid may be used for visualization of axillary lymphatics (see, DeLand et 1980, loc.
cit.). Combined interdigital and periareolar administration of radiocolloid can provide increased accuracy to demonstrate decreased uptake in affected axillary nodes. Intratumoral injection of, e.g., Tc-99m rhenium colloid has been performed in patients with breast cancer and is a useful.mode of administration for certain cases.
Si For lymphoscintigraphy of genitourinary cancers or lesions, bilateral deep perianal injection of radiocolloid and specific imaging agent into the ooo ischiorectal fossa is effective. For example, the patient can be placed in the lithotomy position and about 1 mCi of To-ASC in a volume less than about 0.3 S’ ml is introduced bilaterally into the ischiorectal fossa, with a 22 gauge needle, to a depth of about 1.5 inches just lateral to the anal margin, at o’t the 9 and 3 o’clock positions. The patient may also lie on the side if achieving the lithotomy position is 30 not possible. Subcutaneous dorsal pedal injection of about 1 mCi of Tc-ASC and/or specific imaging agent may be made, using a 27 gauge half-inch needle in the first interdigital spaces bilaterally.
In certain cases, such as testicular or prostatic cancer or some cases of rectal carcinoma, S’ intratumoral or peritumoral injection of imaging agents can be effective.
i The cross-reactive agent is preferably injected Sby a systemic route, intravenously, intraarterially, intramuscularly or subcutaneously, or by a combination of systemic and intralymphatic routes insuring its accretion in both the lymphatic structure of interest and the liver and/or spleen, This technique permits subtraction of the liver and/or spleen which can further refine the imago of the desired lymphatic structure. Another advantage of 17 this approach is its utility in reducing repositioning errors in sequential imaging wherein a patient is imaged in multiple sessions.
The organ image can be used to correlate and superimpose temporally I discrete images by computer matching of the organ image from the separate sessions.
Volumes of colloid preparations are normally about 0.1 2.0 ml, preferably about 0.2 1.0 ml, per injection site, but this can vary depending on the site and the number of injections. Volumes of labeled antibody gross imaging agent, normally in sterile phosphatebuffered aline (PBS) solution or sterile mineral oil suspension, will normally vary somewhat depending upon the site, the concentration and activity of the preparation, and the number of injections.
Activity of the gross agent will normally be in the range of about 0.1 preferably about 0.25 1.5, inCi per injection for a Tc-99rn-labeled agent. Using Tc-ASC, doses of 0.25 1.0 mCi per injection are given for normal, injections. It will be appreciated 2 that the activity will vary for other radioisotopes, depending upon their half-lives, their imaging characteristics, energy ranges, emission intensities, scatter and the like, the stability of the labeled agent, especially antibody conjugates, their rate of transport to the lymph nodes, their distribution and clearance, and the time at which imaging is to be done. Adjustment of these parameters will be 2conventional for the ordinary skilled clinician.
‘**Imaging is normally (effected up to about 6 hours, more preferably at about 2 4 hours after injection of the gross imaging agent, to obtain the “negative” image of the lymphatic structure. Imaging of the localized specific imaging agent is normally effected at about 12 48 hours, preferably at least about 24 hrs post-injection, in order for the non-specifically bound antibody to clear the node. If too much of the specific agent enters the circulation, conventional, subtraction agents, 99m,-pertech-netate and Tc-99m-iTSA can be used to normalize. Alternatively, second antibody, rabbit or goat anti-nmouse IgG, can be injected i.v. to enhance clearance of the specific antibody, as disclosed in Australian patent application 31296/P4 Timing of the injections of gross and specific imaging agents- will depend upon the types of agents used and the drainage patterns to the nodes of interest. Normally, it will take the specific agent a longer time to localize, and for the non-localized agent to clear the nodes, than the time required before imaging can be effected with the gross imaging agent. Thus, if it is desired to image both agents at about the same time, the specific imaging agent may \O need to be injected well before the gross agent.
DeLand et al., 1980, loc. cit., reported imaging at between about 6 and 48 hours post-injection for breast cancer cases, where 1-131-labeled anti-CEA antibody was injected in the webs of the fingers and feet.
Combination of this procedure, according to the invention, with interdigital injection of Tc-ASC is advantageously effected by injection of the colloid about 20 36 hours after injection of the labeled antibody, and imaging of the axillary, subclavian and 20 supraclavicular nodes about 2 hours later, using a collimator which permits separate acquisition of the 1-131 and Tc-99m radiation.
It is generally preferred to effect imaging of both the gross and specific agents at the same time, using separately detectable radionuclides. This avoids the errors associated with repositioning the patient and/or realigning the images by computer.
Consequently, the choice of label for the gross and specific imaging agents and the activities thereof will take into consideration the time intervals for imaging. The specific antibody imaging agent normally will have a label with at least as long a half-life as the gross agent. In the earlier example hereinabove, the antibody is labeled with 1-131, and the gross agent has a Tc-99m label. The antibody could be labeled with In-111 and the gross agent with Ga-67, both of which have about the same half-life of about days. Other pairs of compatible radionuclides for use in labeling the specific and gross imaging agents vO are disclosed in, the above-referenced U.S.
Patent 4,444,744.
In another alternative embodiment of the invention, a labeled specific antibody is administered by a route and mode which ensures accretion in a lymph node to be imaged, an early image is taken when the mtjor portion of the antibody is grossly accreted in the lymph node, after 3 6 hours, and a later image is taken after the major portion of non-localized 19 antibody has cleared and the major portion, at least 5w%, preferably at least about 70%, and more preferably at least about 90%, of the labeled antibody/fragment remaining in the lymph node has been specifically bound by antigen at discrete sites in the structure. The earlier image is then subtracted by computer processing from the later image to generate a refined positive image of the structure.
The scintigram is normally taken by a gamma \O imaging camera having one or more windows for detection of energies in the 50-500 keV range. Use of radioisotopes with high enough energy beta or positron emissions would entail use of imaging cameras with the appropriate detectors, all of which are conventional in the art.
The scintigraphic data are stored in a computer for later processing. Subtraction of the “negative” image obtained with the gross imaging agent sharpens and refines the *’positive” image obtained with the S 20 specific, localized labeled antibody Subtraction is r, effected by the method of DeLand et al., op. cit.., or variants thereof, according to well-known techniques of data processing, normally involving pixel-by-pixel subtraction of normalized values of counts for each channel of the detector, optionally with correction for the counting efficiency of each channel for the radionuclide label detected therein, and conversion of the subtracted values to an output signal to a monochrome or color screen. Where cross-reactive anti- ‘Q o 30 bodies are used as the gross imaging agent, computer subtraction of the image of the cross-reactive organ S, is also effected to further resolve the positive image of the localized antibody site or sites.
If no tumor or lesion is present in the struc- S ture, but marker accretes there by drainage from a proximal tumor or infection, the marker can accrete in discrete foci within the lymph nodes in the drainage path. This can be visualized using the present .A method, since the gross imaging agent will still enable subtraction of areas of only diffuse accretion.
The diagnostic significance of such foci of antigen accretion may be difficult to evaluate, and to distinguish from small metastases, but this problem is common to earlier methods and must be resolved by correlation of imaging data with other diagnostic results. It will be reco:rnized that use of only gross imaging a.gents fails to reveal such antigen localiza- 20 i tion, foci of antigen accretion, which often suggest eventual invasion of tumor cells and also reveal tumor drainage pathways.
Another important application of the organ- or tissue-specific or organ- or tissue-associated antibodies disclosed hereinabove is for normal organ scintigraphy and mri. In this case, a suitably radiolabeled antibody/fragment or an antibody/fragment bearing a mr image enhancing agent is administered \0 with the intention of obtaining a “positive” image of the organ, when normal, and a defect in organ visualization if pathology is present. This provides a new approach to organ and tissue-specific nuclear and magnetic resonance imaging of organs and tissues in the body, based upon their immunological specificity.
It will be understood that the invention is not limited to use of known antibodies or markers, but can be practiced with antibodies to any marker produced by S’ or associated with a tumor or other pathological lesion, Magnetic resonance imaging (mri) is effected in an analogous manner to scintigraphic imaging except that the imaging agents will contain magnetic resonance (mr) enhancing species rather than radioisotopes. It will be appreciated that the magnetic resonance phenomenon operates on a different principle from scintigraphy. Normally, the signal generated is So I correlated with the relaxation -times of the magnetic S” moments of protons in the nuclei of the hydrogen atoms of water molecules in the region to be imaged. The magnetic resonance image enhancing agent acts by increasing the rate of relaxation, thereby increasing the contrast between water molecules in the region where the imaging agent accretes and water molecules elsewhere in the body. However, the offect of the agent is to decrease both T I and T 2 “the former resulting in greater contrast while the latter results in lesser contrast. Accordingly, the phenomenon is concentration-dependent, and there is normally an optimum concentration of a paramagnetic species for maximum efficacy. This optimal concentration will vary with the particular agent used, the locus of imaging, the mode of imaging, spin-echo, saturation-recovery, inversion-recovery and/or various other strongly T 1 -dependent or T 2 -dependent imaging techniques, and the composition of the medium in which the agent is dissolved or suspended.
21 These factors, and their relative importance are known in the art. See, Pykett, Scientific American, 246, 78(1982); Runge et al., Am. J. Radiol., 141, 1209(1983).
Again, the gross agent can be a colloid or a labeled antibody to a normal component of lymphatic structures, labeled with a paramagnetic ion or radical which can significantly alter the relaxation time of protons in water molecules in its vicinity. It is \O also possible to use an agent containing a high concentration of atoms of an element other than hydrogen, having a strong nuclear magnetic moment which is detectable by an nmr detector, Fluorine-19 and the like, and which can also be accreted in a lymphatic structure in an amount sufficient for efficient nmr detection.
Examples of RE colloids useful for mri of S’ lymphatic systems include Gd(III), Eu(III), Dy(III), S’ Pr(III), Pa(IV), Mn(II), Cr(III), Co(III), Fe(III), Cu(II), Ni(II), Ti(III) and V(IV) colloids, colloids O i of other strongly paramagnetic ions, or radicals, nitroxides, and antibody conjugates bearing I’ paramagnetic ion chelates or radical addends. The latter will include paramagnetic conjugates with antibodies to lymphatic structures or lymphocytes, for use as gross imaging agents, as well as conjugates with antibodies to tumor or lesion markers for use as o specific imaging agents.
The specific imaging agent can use the same 1 30 image enhancing agent, with mri effected at different times from the gross imaging, or a label which is separately and independently detectable with an nmr imaging camera, in the presence of the agent used for gross imaging. Examples of the latter strategy 4 include, use of antibody conjugates with heavy loadings of’ d(III) or Mn(II) cholates as the specific imaging agent, where the gross imaging agent is a colloid containing a high concentration of fluorine atoms or atoms of another suitable element having a ko strong nuclear magnetic moment, whose nuclear magnetic resonance frequency occurs at a widely different value from that of -he hydrogen nucleus.
The mr image enhanclng agent must be present in sufficient amounts to ena le detection by an external camera, using magnetic field strengths which are reasonably attainable and compatible with patient 22 safety and instrumental design. The requirements for such agents are well known in the art for those agents which have their effect upon water molecules in the medium, and are disclosed, inter alia, in Pykett, op. cit., and Runge et al., op. cit.
Preparation of antibodies conjugated to a magnetic resonance image enhancing agent can be effected by a variety of methods. In order to load an antibody molecule with a large number of paramagnetic ions, it may be necessary to react it with a reagent having a long tail to which are attached a multiplicity of chelating groups for binding the ions. Such a tail can be a polymer such as a polylysine, polysaccharide, or other derivatized or derivatizable chain having pendant groups to which can be bound chelating groups such as, e.g., ethylenediaminetetra-acetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), porphyrins, polyamines, crown ethers, bis-thiosemicarbazones, polyoximes, and the like groups known to be useful for this purpose. The chelate is normally linked to the antibody by a ~group which enables formation of a bond to the antibody with minimal loss of immunoreactivity and minimal aggregation and/or internal crosslinking. Other, more unusual, methods and reagents for conjugating chelates to antibodies are disclosed in U.S. patent 4,824,659 to Hawthorne, entitled “Antibody Conjugates”, filed June 7, 1985, the disclosure of which is incorporated herein in its entirety by reference.
4o°44 The mr scans are stored in a computer and the image subtraction is effected analogously to the scintigraphic data.
I o” Reagents for use in the method of the invention include radiocolloids, radiolabeled antibodies/fragments which specifically bind to markers produced by or associated with tumors and infectious 4 lesions, radiolabeled antibodies/fragments which specifically bind to lymphatic structural components, including tissues and lymphocytes, radiolabelled antibodies/fragments which specifically bind to normal organ tissues, and the analogous imaging agents labeled with mr image enhancers,, as disclosed hereinabove. These will be packaged separately or together, depending upon whether they are to be injected simultaneously oir separately, or whether or not they are labeled at the site of administration or at a remote location.
S23 i I~P I The reagents are conveniently provided in kit form, adapted for use in the method of the invention.
Kits will normally contain separate sealed sterile vials of injectable solutions of labeled reagents, or lyophilyzed antibodies/fragments or antibody/fragment conjugates and vials of suitable conventional injection vehicles with which they will be mixed just prior to administration.
Kits may also include reagents for labeling \O antibodies, Chloramine-T (for 1-131 or 1-123 labeling), SnC12 (for To-99m labeling using pertechnetate from a commercial generator), short columns for sizing and/or purification of reagents, and other conventional accessory materials.
Without further elaboration, it is believed that 6640 one skilled in the art can, using the preceding 00O description, utilize the present invention to its *fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely 4 20 illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. In the following examples, all temperatures are set forth uncorrected in degrees Celsius; unless otherwise indicated, all parts and percentages are by weight.
EXAMPLE 1 409 0 Preparation of lymphoscintigraphic reagents.
a) a-67-laboled Ti01 anti-lymphocyto monoclonal antibody A sample of T101 anti-lymphocyte murine 2 monoclonal antibody, as reported by Royston et al., loe. cit., is labeled with Ga-67 by the mthed of 00, Hnatowioh ot al., Sciono, 220, 613(1983), to form the 0 Dconjugate with a diethylonetriaminpnctaacetate
(DTPA)
gallium(ITI) chelate, containing an average of 4 Ga’ atoms per antibody molecule, and retaining at least of its initial immunorecotivity. A solution of the antibody in PBS, pI 7.4, is added to a molar oxcess of solid DTPA dianhydrider and agitated for 5 minutes. Free DTPA is removed by gel filtration -AO on Sephadex 0 50, About 1 mCi Ga-67 citrate is added per mg of antlbody-DTPA, conjugate, and incubated for minutes, and unbound Ga-67 is then removed, otg., by gel filtration on Sophadox C 50, The resultant Ca-67-DTPA-T1OI has a speoific activity of about 0,5 1 .5 mCi/mg.
24 L I- i ~x ll~~rrulr*~*~rr~ urCro r- I b) I-131-labeled T101 anti-lymphocyte monoclonal antibody A sample of the T101 monoclonal antibody used in Example 1 is labeled with I-131 according to the procedure of Example 1(f) of U.S. Patent 4,348,376, using Chloramine-T and replacing the anti-CEA antibody used in the .referenced procedure with an equal weight of T101 antibody, but reducing the amounts of reagents to lower the iodine content. The resultant I-131-Tiol O has an average of 1 atom of iodine per antibody molecule and a specific activity of about 12 mCi/mg.
c) In-11il-labeled anti-IITLV-1 monoclonal antibody A sample of murine monoclonal anti–TLV-1 antibody is labeled with In-11i according to the procedure of part hereof, except that In-11i oxinate is used instead of Ga-67 citrate, to form the conjugate with a DTPA indium(TII) chlate, containing an average of In atoms per antibody molecule, and retaining at least 70% of its initial immunoreac- ZO tivity. The resultant In-1i1-DTPA-anti-IITLV-1 has a spacific activity of about 0,5 1.5 mCi/mg.
d) In-ll-labeled anti-prostat ic acid phosphatase F(ab’-) 2 A sample of anti-prostatic acid phosphatase (PAP) F(ab’)2, prepared by the method disclosed in U.S. 4,31,647, and described in Goldenborg et al,, i.
Am. Med Assn., 250, 630(1983), is labeled with In-111, using the procedure of part hereofe The resultant In-111-DTPA-chelate conjugate contains an aveage of 3 SIn atoms per antibody fragment, and retains at least of its initial immunoroacltivity. It has a specific activity of about 2 mCi/mg.
e) 1-123-labeled anti-CEIA monoclonal antibody
II
A sample of the NP-2 monoclonal antibody which 6pecifically binds to carcinoembryonio antigan (CEA), disclosed in U.S.SJN. 609,607 iq labeled with 1-123 according to the procedure of Example 1(f) of U.S.
Patent 4,348,376, using Chloramino-T and replacing the 1-131 used in the referenced procedure with an equal L\ weight of 1-123, but reducing the amounts of reagents to lower the iodine content. The resultant 1-123-anti-CEA IgG has an avorage of 1 atom of iodine per antibody molecule and a specific activity of about 12 mCi/mg.
21 EXAMPLE 2 Preparation of injectable lymphoscintigraphy compositions Sterile, pyrogen-free solutions are prepared as shown.
a) A sterile solution )ntaining, per ml: 1) 10 mg Human Serum Albumin (HSA) USP, Parke-Davis) 2) 0.01 M phosphate buffer, pH 7.5 (Bioware) 3) 0.9% NaCi 4) 1.5 mg Ga-67-DTPA-T101 antibody prepared according to Example la, b) A sterile solution according to Example 2a, except that 250 ug of the I-131-labeled antibody according to Example lh is present instead of the Ga-labeled antibody.
c) A sterile solution according to Example 2a, except that 1.5 mg of the In-ll-labeled antibody according tc Example lc is Rsent instead of the Ga-labeled antibody.
d) A sterile solxztion according to Example 2a, except that 1.5 mg ~E the In-lll-labeled antibody according to Example id is present instead of the Ga-labeled antibody.
e) A sterile solution according to Example 2a, except that 250 ug of the 1-123-labeled antibody according to zxample le is present instead of the Ga-labeled antibody.
EXAMPLE 3 Preparation of Reagents for NMR Lymphography a) Preparation of Gd-labeled anti-CEA A sample of murine monoclonal antibody to carcinembryonic antigen (CEA), prepared according to Example 2 of U.S, Patent 4,348,376 or according to Examples 6 and 7 of Australian patent application 24931/84, is labeled with a p-isothiocyanatobenzoyl-capped oligothiourea containing 320 Gd(III)-DTPA chelate groups U5 Pokes NOo, -Qg prepared according to Example 11 of4 P end-lI r.
26 to put an average of 5 oligothiourea chains on the antibody, without loss of more than 30% immunoreactivity and without significant aggregation of the antibody conjugate. The resultant conjugate carries an average of 320 gadolinium ions thereon. The reaction is effected in 0.1 M aqueous Na 2
CO
3 NaHC03 buffer, at pH 8.5, at room temperature, with at least a 50-fold excess of the polymer, and an antibody concentration of about 10 mg/ml.
\D The conjugate is purified by gel filtration on a column of allyl dextran cross-linked with N,N’-methylene bisacrylamide, Sephacryl S-200 (Pharmacia Fine Chemicals, Piscatoway, b) Preparation of Gd(III)-labeled T101 monoclonal antibody SA sample of T101 murine monoclonal antibody is labeled with about 320 Gd ions by the procedure of part hereof, except that the antibody is the T101 antibody instead of monoclonal anti-CEA IgG. The a” 0 resultant conjugate is isolated by an analogous procedure to the foregoing part of this Example.
0″ c) Preparation of Cu(II) sulfide colloid CuS sulfur colloid is prepared by bubbling H 2
S
1, «into an acidified solution of CuC12, in the presence S of oxygen and gelatin, and isolating the resultant S% colloid.
0 I I; EXAMPLE 4 Preparation of injectable mri compositions 0* Sterile, pyrogen-free solutions are preparede as 2 Shown.
a) A sterile solution containing, per ml: 1) 10 mg Human Serum Albumin (MSA) USP, Parke-Davis) 2) 0.01 M phosphate buffer, p1H 7.5 (Bioware) 3) 0.9% NaC1 4) 1.5 mg Gd-labeled anti-CEA IgG prepared according to Example 3a.
27 i i b) A sterile solution according to Example 4a, except that 1.5 mg of the Gd-labeled T101 according to Example 4b is present instead of the Gd-labeled anti-CEA.
EXAMPLE Lymphoscintigraphy A male with proven prostatic carcinoma is being evaluated for ileopelvic lymph node spread. He is positioned supine on the pelvic examination table in \O the lithotomy position. Two injections (approximately 2 mCi each) of Tc-99m-ASC (as supplied by Cadema Medical, Inc., Westtown, N.Y. 10998) and of 111-In-labeled F(ab’) 2 against prostatic acid phosphatase (PAP) prepared according to Example 2(d) herein, are made just lateral to the anal margin, at 3 and 9 o’clock. The needle is held parallel to the tabletop and is inserted to its full length of 1 1/2 inches (22-gauge) into the ischiorectal fossa. Within each injection is contained 1 mCi each of the 99m-Tc O and the 111-In preparation, which are mixed in the syringe for simultaneous application. (It may be preferred to first inject the antibody fragment and then, 1-2 hrs. later, the antimony sulfide colloid.) 4 About 3 hrs after the injections, the patient is imaged with a medium-resolution collimator, collecting about 100,000 to 200,000 counts per view, followed by repeated imaging at 8 and 24 hours. Images are taken in the anterior, posterior, and lateral projections.
The images made by the two isotopes with different S D0 energies are then computer-subtracted according to the method described by DeLand et al., Cancer Res., 3046(1980), whereby the lymph-node image of the Tc-99m-ASC is subtracted, pixel-by-pixel, from that of the In-111-labeled anti-PAP antibody fragment. At 3 hrs after injection of the preparations, and again .at 8 hrs., the right obturator and internal iliac nodes are visualized as having abnormal radioactivity following pcrianal injection. Images of the 99m-Tc colloid alone or of the 111-In-antibody alone were L\O equivocal for lymph node involvement, indicating the superiority of the combined (double isotope and agent) approach.
28 EXAMPLE 6 Lymphoscintigraphy A patient with carcinoma of her right breast receives injections of approximatel; 0.25 mCi 131-I-labeled T101 monoclonal antibody, according to Example subcutaneously in the web of the fingers of both hands (totalling 0.7 to 1.5 mCi 131-I). The patient also receives, in the same injections, 1.5 mCi 123-I-labeled monoclonal anti-CEA antibody NP-2, \0 according to Example (totalling 4.2 to 9.0 mCi 123-1). Before administration of the labeled antibodies, the patient is skin-tested for allergic reaction to mouse IgG, and also receives Lugol’s iodine to minimize radioiodine concentration by the thyroid gland. Immediately following the subcutaneous injection, the areas are massaged for several minutes, and the patient is asked to exercise her fingers.
By means of a gamma camera, images are obtained S* at frequent intervals, starting at 2 hrs. after injection and ending at 36 hrs. The data are stored in a laboratory computer and the images generated on a color display system. The 131-I images are then subtracted, pixel-by-pixel, from the 123-I images by computer processing. The metastatic foci in the ipsilateral axillary lymph node appear as early as 4 hrs., and more clearly at 6 hrs., after injection as a discrete focus of increased radioactivity, while the contralateral axillary nodes are negative. Two weeks a n later, the same procedure is repeated and the results 30 confirmed, except that this time, 111-In is used to label the T101 monoclonal antibody.
Another study with 99m-To sulfide colloid injected simultaneously with 111-In-labeled anti-CEA monoclonal antibody, effected as above but with the appropriate doses for these radionuclides and agents, is repeated a month later and the right axillary lymph node involvement is seen again.
EXAMPLE 7 Lymphoscintigraphy u0) A 24 year old male presents with left side inguinal node enlargement and has a constellation of symptoms and history suggestive of AIDS. 67-Ga- 29 _II ,I -i YYIIVIY YPP LPIPI~ labeled T101 monoclonal antibody, according to Example is injected in divided doses into the web of the toes of both feet, with a total dose of 4 mCi, At the same time and in the same injections, an equal dose of 111-In-labeled monoclonal antibody against HTLV-1, according to Example is injected. Beginning at 2 hrs post-injection and continuing at intervals of 2 hrs up to a total of 6 hrs, and then again at 24′ hrs., the patient’s inguinal region and pelvis is imaged \O with a medium-energy collimator and using the subtraction method described above to subtract the 67-Ga images from the 111-In images. At 4 hrs, and then improving by 6 hrs., a positive image of the left inguinal node is noted while the right inguinal node virtually negative.
EXAMPLE 8 Organ Scintigraphy Hybridoma-monoclonal antibodies are made in the *4 mouse to the Langerhans cells of the endocrine 1, pancreas, derived from a human autopsy specimen shortly after death. The monoclonals reactive against the antigen epitopes showing relatively high specificity for Langerhans cells of the pancreas, as demonstrated, by immunohistology, are labeled with a gamma-emitting isotope, such as with 1-131, and 0 4 ,injected, 0.15 mg monoclonal against endocrine pancreas antigen, labeled using Chloramine-T with 1-131, at a dose of 1.0 mCi, injected i.v. in i 3-month old male suspected of having pathology of the 7o endocrine pancreas. External gamma-camera imaging is performed at 24, 48, 72, and 96 hours after injection, without subtraction. In this specific case, decreased to almost absent accretion of 1-131 radioactivity in the pancreas is suggestive of endocrine pancreas pathology in an infant presenting with pancreas hormone deficiency shortly after birth.
30
-C;
The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
From the foregoing description, one skilled in the art can easily ascertain the essential- characteristics of this invention and, without departing from the spirit and scope thereof, can make various 3O changes and modifications of the invention to adapt it to various usages and conditions.
e4 4 o 0 o I I o S0t 0 I 1 _1

Claims (9)

1. A lymphographic imaging method for imaging of a tumor or infectious lesion or a localized product thereof in a mammalian lymphatic structure, comprising the steps of: parenterally injecting a mammalian subject, at a locus and by a route providing access to said lymphatic structure, with an amount of a gross lymphoscintigraphic imaging agent or lymphoiiagnetic resonance image enhancing agent sufficient to permit a scintigraphic image or an enhanced magnetic resonance image of said structure to be effected; and obtaining a gross positive scintigraphic image or a gross positive enhanced magnetic resonance image of said structure, at a time after injection of said agent sufficient for said agent to diffusely accrete in said structure, wnerein said gross imaging agent comprises an antibody or antibody fragment which specifically binds to normal lymphatic cells or tissues, said antibody or antibody fragment being labelled with a radioisotope or a magnetic resonance image enhancing agent; and wherein a tumor or infectious lesion or a localized product thereof in said structure is revealed as a negative image.

2. The method of claim 1, wherein said antibody or antibody fragment is labelled with a magnetic resonance image enhancing agent.

3. The method of claim 1, wherein said rntibody or antibody fragment is labelled with a radioisotope.

4. A method of organ imaging in a mammalian subject by scintigraphy or magnetic resonance imaging, comprising the steps of: parenterally injecting a mammalian subject, at a locus and by a route providing access to an organ of interest, with an antibody or antibody fragment which specifically binds a marker produced by or associated with rln fX p4 33 ii if I I; oirtt o i, o *B i)lr iCf 80 n said organ, said antibody or antibody fragment being labelled with a radioisotope capable of external detection or with a magnetic resonance image enhancing agent, the amount of the labelled antibody or antibody fragment being sufficient to permit a scintigraphic image or an enhanced magnetic resonance image of said organ to be obtained; and obtaining a positive scintigraphic or a positive enhanced magnetic resonance image of said organ, at a time after injection of said agent sufficient for said agent to diffusely accrete in said organ and specifically bind to said marker.

5. The method of claim 4, wherein said marker is an intracellular marker.

6. The method of claim 4, wherein said antibody or antibody fragment is labelled with a magnetic resonance image enhancing agent.

7. The method of claim 4, wherein said antibody or antibody fragment is labelled with a radioisotope.

8. A lymphographic imaging kit when used in the lymphographic imaging method of claim i, comprising: a gross imaging agent comprising an antibody/ fragment which specifically binds to normal lymphatic cells or tissues, said antibody/fragment being labelled with a radioisotope or a magnetic resonance enhancing agent; and a sterile, pharmaceutically acceptable injection vehicle.

9. An organ imaging kit when used in the method of claim 4, comprising: an antibody or antibody fragment which specifically binds a marker produced by or associated with an organ, the antibody or antibody fragment being labelled with a radioisotope capable of external detection or with a magnetic resonance imaging enhancing agent; and L~ r_ 34 a sterile, pharmaceutically acceptable injection vehicle. DATED this 4th day of November 1991 MILTON DAVID GOLDENBERG Patent Attorneys for the Applicant: F.B. RICE CO.

AU34959/89A
1985-07-05
1989-05-18
Lymphographic imaging method and kit

Ceased

AU619291B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US06/751,877

US4735210A
(en)

1985-07-05
1985-07-05
Lymphographic and organ imaging method and kit

US751877

2000-12-28

Related Parent Applications (1)

Application Number
Title
Priority Date
Filing Date

AU59728/86A
Division

AU589428B2
(en)

1985-07-05
1986-07-03
Lymphographic imaging method and kit

Publications (2)

Publication Number
Publication Date

AU3495989A

AU3495989A
(en)

1989-09-14

AU619291B2
true

AU619291B2
(en)

1992-01-23

Family
ID=25023897
Family Applications (2)

Application Number
Title
Priority Date
Filing Date

AU59728/86A
Ceased

AU589428B2
(en)

1985-07-05
1986-07-03
Lymphographic imaging method and kit

AU34959/89A
Ceased

AU619291B2
(en)

1985-07-05
1989-05-18
Lymphographic imaging method and kit

Family Applications Before (1)

Application Number
Title
Priority Date
Filing Date

AU59728/86A
Ceased

AU589428B2
(en)

1985-07-05
1986-07-03
Lymphographic imaging method and kit

Country Status (9)

Country
Link

US
(1)

US4735210A
(en)

EP
(1)

EP0208531B1
(en)

JP
(1)

JPH07116060B2
(en)

AT
(1)

ATE120965T1
(en)

AU
(2)

AU589428B2
(en)

CA
(1)

CA1271522A
(en)

DE
(1)

DE3650296T2
(en)

IL
(1)

IL79333A
(en)

ZA
(1)

ZA864987B
(en)

Families Citing this family (140)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5776093A
(en)

*

1985-07-05
1998-07-07
Immunomedics, Inc.
Method for imaging and treating organs and tissues

EP0247156B1
(en)

*

1985-11-18
1993-06-23
Access Pharmaceuticals Inc.
Polychelating agents for image and spectral enhancement (and spectral shift)

US5336762A
(en)

*

1985-11-18
1994-08-09
Access Pharmaceuticals, Inc.
Polychelating agents for image and spectral enhancement (and spectral shift)

USRE38008E1
(en)

1986-10-09
2003-02-25
Neorx Corporation
Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof

US5019368A
(en)

*

1989-02-23
1991-05-28
Cancer Biologics, Inc.
Detection of necrotic malignant tissue and associated therapy

US5032678A
(en)

*

1986-12-30
1991-07-16
Nihon Medi-Physics Co., Ltd.
Radio labeled high molecular compound comprising unit of asialoglycoprotein acceptor-directing compound and unit of chelate forming compound chemically bonded thereto

US5084266A
(en)

*

1988-02-03
1992-01-28
The University Of Melbourne
Method for tumor imaging utilizing a labelled tumor specific antibody and a non-tumor reactive antibody

US5681543A
(en)

*

1988-02-29
1997-10-28
Shering Aktiengesellschaft
Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI

US4925648A
(en)

*

1988-07-29
1990-05-15
Immunomedics, Inc.
Detection and treatment of infectious and inflammatory lesions

US5439665A
(en)

*

1988-07-29
1995-08-08
Immunomedics
Detection and treatment of infectious and inflammatory lesions

US5213788A
(en)

*

1988-09-29
1993-05-25
Ranney David F
Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement

US5260050A
(en)

*

1988-09-29
1993-11-09
Ranney David F
Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes

GB2223572B
(en)

*

1988-10-04
1992-10-28
Rolls Royce Plc
Detecting trapped material within a hollow article using radiation

EP0437479B1
(en)

*

1988-10-05
1994-06-22
Vestar, Inc.
Method of making liposomes with improved stability during drying

US5948634A
(en)

*

1988-12-21
1999-09-07
The General Hospital Coporation
Neural thread protein gene expression and detection of alzheimer’s disease

US5059415A
(en)

*

1989-02-21
1991-10-22
The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon Health
Method for diagnostically imaging lesions in the brain inside a blood-brain barrier

US5308604A
(en)

*

1989-04-19
1994-05-03
Deutsches Krebsforschungsinstitut
Conjugates for tumor localization and/or tumor therapy

US5230883A
(en)

*

1989-05-04
1993-07-27
Wisconsin Alumni Research Foundation
Method for localization and treatment of tumors using polylysine complexes

US5114703A
(en)

*

1989-05-30
1992-05-19
Alliance Pharmaceutical Corp.
Percutaneous lymphography using particulate fluorocarbon emulsions

EP0513000B1
(en)

*

1989-11-27
1996-07-31
Concat Ltd.
Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands

KR0162259B1
(en)

*

1989-12-05
1998-12-01
아미 펙터
Chimeric antibody for detection and therapy of infectious and inflammatory lesions

US5130129A
(en)

*

1990-03-06
1992-07-14
The Regents Of The University Of California
Method for enhancing antibody transport through capillary barriers

US5277892A
(en)

*

1990-08-08
1994-01-11
Rhomed Incorporated
In vivo lymphocyte tagging

US5310539A
(en)

*

1991-04-15
1994-05-10
Board Of Regents, The University Of Texas System
Melanin-based agents for image enhancement

AU2307092A
(en)

*

1991-07-01
1993-02-11
Mallinckrodt Medical, Inc.
Tissue specific imaging agents using internal image anti-idiotypic antibodies

WO1993006117A1
(en)

*

1991-09-25
1993-04-01
The General Hospital Corporation
Sf-25 antibodies, especially chimeric antibodies, with specificity for the human tumor sf-25 antigen, methods for their production, and uses thereof

US5643549A
(en)

*

1992-02-20
1997-07-01
Rhomed Incorporated
Leukostimulatory agent for in vivo leukocyte tagging

JPH07509467A
(en)

*

1992-07-21
1995-10-19
ザ　ゼネラル　ホスピタル　コーポレーション

Drug transport system to lymphoid tissue

US7713528B1
(en)

*

1993-02-18
2010-05-11
Enzo Therapeutics, Inc.
Method for in vivo delivery of active compounds using reagent conjugate

US5595721A
(en)

1993-09-16
1997-01-21
Coulter Pharmaceutical, Inc.
Radioimmunotherapy of lymphoma using anti-CD20

EP1304085A3
(en)

1994-09-16
2004-01-21
Ethicon Endo-Surgery, Inc.
Biodegradable tissue marking device

US6107090A
(en)

1996-05-06
2000-08-22
Cornell Research Foundation, Inc.
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains

US6136311A
(en)

1996-05-06
2000-10-24
Cornell Research Foundation, Inc.
Treatment and diagnosis of cancer

US5994409A
(en)

1997-12-09
1999-11-30
U.S. Bioscience, Inc.
Methods for treatment of neuro–and nephro–disorders and therapeutic toxicities using aminothiol compounds

US6962702B2
(en)

*

1998-06-22
2005-11-08
Immunomedics Inc.
Production and use of novel peptide-based agents for use with bi-specific antibodies

US7387772B1
(en)

1999-06-22
2008-06-17
Immunimedics, Inc.
Chimeric, human and humanized anti-CSAP monoclonal antibodies

US7833528B2
(en)

*

1998-06-22
2010-11-16
Immunomedics, Inc.
Use of multispecific, non-covalent complexes for targeted delivery of therapeutics

US7405320B2
(en)

1998-06-22
2008-07-29
Immunomedics, Inc.
Therapeutic and diagnostic conjugates for use with multispecific antibodies

US7138103B2
(en)

*

1998-06-22
2006-11-21
Immunomedics, Inc.
Use of bi-specific antibodies for pre-targeting diagnosis and therapy

US6361774B1
(en)

1999-09-17
2002-03-26
Immunomedics, Inc.
Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug

EE05627B1
(en)

*

1998-12-23
2013-02-15
Pfizer Inc.

Human monoclonal antibodies to CTLA-4

US7109003B2
(en)

1998-12-23
2006-09-19
Abgenix, Inc.
Methods for expressing and recovering human monoclonal antibodies to CTLA-4

CA2356215C
(en)

1998-12-23
2015-11-24
Pfizer Inc.
Human monoclonal antibodies to ctla-4

US6371904B1
(en)

*

1998-12-24
2002-04-16
Vivant Medical, Inc.
Subcutaneous cavity marking device and method

US6356782B1
(en)

*

1998-12-24
2002-03-12
Vivant Medical, Inc.
Subcutaneous cavity marking device and method

US9669113B1
(en)

1998-12-24
2017-06-06
Devicor Medical Products, Inc.
Device and method for safe location and marking of a biopsy cavity

MY133346A
(en)

1999-03-01
2007-11-30
Biogen Inc
Kit for radiolabeling ligands with yttrium-90

US20020102208A1
(en)

1999-03-01
2002-08-01
Paul Chinn
Radiolabeling kit and binding assay

US6489312B1
(en)

1999-06-15
2002-12-03
Medimmune Oncology, Inc.
Pharmaceutical formulations comprising aminoalkyl phosphorothioates

US7605238B2
(en)

*

1999-08-24
2009-10-20
Medarex, Inc.
Human CTLA-4 antibodies and their uses

US6984720B1
(en)

1999-08-24
2006-01-10
Medarex, Inc.
Human CTLA-4 antibodies

US20030031670A1
(en)

*

1999-11-08
2003-02-13
Jack R. Wands
Diagnosis and treatment of malignant neoplasms

US20050123545A1
(en)

*

1999-11-08
2005-06-09
Wands Jack R.
Diagnosis and treatment of malignant neoplasms

US6835370B2
(en)

*

1999-11-08
2004-12-28
Rhode Island Hospital
Diagnosis and treatment of malignant neoplasms

AU2002252444A1
(en)

*

2001-03-23
2002-10-08
Board Of Regents, The University Of Texas System
Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors

US7514078B2
(en)

2001-06-01
2009-04-07
Cornell Research Foundation, Inc.
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies

WO2002098897A2
(en)

2001-06-01
2002-12-12
Cornell Research Foundation, Inc.
Modified antibodies to prostate-specific membrane antigen and uses thereof

JP2004538269A
(en)

*

2001-06-11
2004-12-24
ユニバーシティー オブ マイアミ

Use of radiopharmaceutical conjugates in achieving transplant tolerance

CA2452288A1
(en)

2001-09-20
2003-03-27
Cornell Research Foundation, Inc.
Methods and compositions for treating and preventing skin disorders using binding agents specific for psma

US8323903B2
(en)

*

2001-10-12
2012-12-04
Life Technologies Corporation
Antibody complexes and methods for immunolabeling

AR039067A1
(en)

2001-11-09
2005-02-09
Pfizer Prod Inc

ANTIBODIES FOR CD40

JP2005516965A
(en)

*

2001-12-28
2005-06-09
アブジェニックス・インコーポレーテッド

Method using anti-MUC18 antibody

AU2002361886A1
(en)

*

2001-12-28
2003-07-24
Abgenix, Inc.
Antibodies against the muc18 antigen

ATE394121T1
(en)

*

2001-12-28
2008-05-15
Amgen Fremont Inc

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

US6578724B1
(en)

*

2001-12-29
2003-06-17
United States Can Company
Connector for use in packaging aerosol containers

WO2003077864A2
(en)

*

2002-03-15
2003-09-25
Department Of Veterans Affairs, Rehabilitation R & D Service
Methods and compositions for directing cells to target organs

SI1503794T1
(en)

*

2002-04-12
2012-09-28
Medarex Inc
Methods of treatement using ctla-4 antibodies

EP1554575A2
(en)

*

2002-10-10
2005-07-20
The U.S. Government represented by The Department of Veterans Affairs
Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope

AU2003286493A1
(en)

*

2002-10-18
2004-05-04
Abgenix, Inc.
System and method for cleaving antibodies

AU2003298816C1
(en)

2002-12-02
2010-12-16
Amgen Fremont, Inc.
Antibodies directed to Tumor Necrosis Factor and uses thereof

JP2006510653A
(en)

*

2002-12-12
2006-03-30
マノア メディカル， インコーポレイテッド

Percutaneous excision of sentinel lymph nodes using a contrast medium for identification

WO2004063701A2
(en)

2003-01-10
2004-07-29
Millennium Pharmaceuticals, Inc.
Methods of diagnosing and treating cancer

CA2519528C
(en)

2003-03-19
2016-01-26
Abgenix, Inc.
Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof

CA2529027C
(en)

*

2003-06-13
2013-09-10
Immunomedics, Inc.
D-amino acid peptides

KR20130083463A
(en)

2003-06-27
2013-07-22
암젠 프레몬트 인코포레이티드
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

CA2533878A1
(en)

*

2003-07-29
2005-09-22
Immunomedics, Inc.
Fluorinated carbohydrate conjugates

AU2005264063B2
(en)

2004-07-16
2009-09-10
Pfizer Products Inc.
Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody

DK1827492T3
(en)

2004-11-30
2010-11-22
Curagen Corp

Antibodies targeting GPNMB and uses thereof

AU2005319404B2
(en)

2004-12-20
2011-10-20
Amgen Fremont Inc.
Binding proteins specific for human Matriptase

ES2665422T3
(en)

2005-03-03
2018-04-25
Immunomedics Inc.

Humanized L243 antibodies

ES2716874T3
(en)

2005-03-23
2019-06-17
Genmab As

Antibodies against cd38 for the treatment of multiple myeloma

WO2006104677A2
(en)

2005-03-24
2006-10-05
Millennium Pharmaceuticals, Inc.
Antibodies that bind ov064 and methods of use therefor

AU2006278260B2
(en)

*

2005-08-08
2012-03-08
Onconon, Llc.
Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility

CA2618807C
(en)

*

2005-08-12
2015-01-06
University Health Network
Methods and devices for lymphatic targeting

JP2009515897A
(en)

2005-11-10
2009-04-16
キュラジェン コーポレイション

Methods of treating ovarian and renal cancer using antibodies to immunoglobulin domains of murine domain and mucin domain 1 (TIM-1) antigen

NZ568016A
(en)

2005-12-07
2011-12-22
Medarex Inc
CTLA-4 antibody dosage escalation regimens

RS52357B
(en)

2005-12-13
2012-12-31
Medimmune Limited
Binding proteins specific for insulin-like growth factors and uses thereof

EP2674440B1
(en)

2005-12-16
2019-07-03
IBC Pharmaceuticals, Inc.
Multivalent immunoglobulin-based bioactive assemblies

AU2007234733A1
(en)

*

2006-04-07
2007-10-18
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services
Antibody compositions and methods for treatment of neoplastic disease

TW200813091A
(en)

2006-04-10
2008-03-16
Amgen Fremont Inc
Targeted binding agents directed to uPAR and uses thereof

CL2007002225A1
(en)

2006-08-03
2008-04-18
Astrazeneca Ab

SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A

WO2015164330A1
(en)

2014-04-21
2015-10-29
Millennium Pharmaceuticals, Inc.
Anti-psyk antibody molecules and use of same for syk-targeted therapy

JP5778577B2
(en)

2008-09-19
2015-09-16
メディミューン，エルエルシー

Antibodies against DLL4 and uses thereof

UA109633C2
(en)

2008-12-09
2015-09-25

HUMAN ANTIBODY AGAINST TISSUE FACTOR

AU2009331528A1
(en)

2008-12-23
2011-08-11
Astrazeneca Ab
Targeted binding agents directed to alpha5beta1 and uses thereof

US8137671B2
(en)

2009-05-05
2012-03-20
Genentech, Inc.
Anti-IL-17F antibodies

UA108991C2
(en)

2009-10-23
2015-07-10
Милленниум Фармасьютикалз, Инк.
Anti-gcc antibody molecules and related compositions and methods

PT3279215T
(en)

2009-11-24
2020-05-18
Medimmune Ltd
Targeted binding agents against b7-h1

SI2580243T1
(en)

2010-06-09
2020-02-28
Genmab A/S
Antibodies against human cd38

PL2582728T3
(en)

2010-06-15
2018-01-31
Genmab As
Human antibody drug conjugates against tissue factor

AR083546A1
(en)

2010-10-25
2013-03-06
Genentech Inc

TREATMENT OF GASTROINTESTINAL INFLAMMATION, SORIASIS AND ASTHMA

US9211302B2
(en)

2011-01-17
2015-12-15
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Modulation of LRCH4 activity and therapeutic application thereof

WO2012136552A1
(en)

2011-04-08
2012-10-11
H. Lundbeck A/S
ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ

US9150644B2
(en)

2011-04-12
2015-10-06
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II

WO2012143523A1
(en)

2011-04-20
2012-10-26
Genmab A/S
Bispecifc antibodies against her2

UA117901C2
(en)

2011-07-06
2018-10-25
Ґенмаб Б.В.
Antibody variants and uses thereof

AP2014007638A0
(en)

2011-11-16
2014-05-31
Amgen Inc
Methods of treating epidermal growth factor deletion mutant VIII related disorders

KR102100388B1
(en)

2012-02-06
2020-04-13
인히브릭스, 인크.
Cd47 antibodies and methods of use thereof

US9156915B2
(en)

2012-04-26
2015-10-13
Thomas Jefferson University
Anti-GCC antibody molecules

CN104736174B
(en)

2012-07-06
2019-06-14
根马布私人有限公司
Protein dimer with triple mutant

EP3632462A1
(en)

2012-07-06
2020-04-08
Genmab B.V.
Dimeric protein with triple mutations

EA201500741A1
(en)

2013-01-10
2016-01-29
Генмаб Б.В.

HUMAN FG IGG1 OPTIONS AND THEIR APPLICATION

TWI682941B
(en)

2013-02-01
2020-01-21
美商再生元醫藥公司
Antibodies comprising chimeric constant domains

WO2014123580A1
(en)

2013-02-06
2014-08-14
Inhibrx Llc
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof

US9931412B2
(en)

2013-02-08
2018-04-03
The Regents Of The University Of Michigan
Targeted theranostics

BR112015020587A2
(en)

2013-03-14
2017-10-10
Regeneron Pharma

apelin fusion proteins and their uses

EP3705494A3
(en)

2013-08-14
2020-12-09
Sachdev Sidhu
Antibodies against frizzled proteins and methods of use thereof

CN105722850B
(en)

2013-08-19
2020-03-06
雅培分子公司
Nucleotide analogs

WO2015103026A2
(en)

2014-01-03
2015-07-09
The Regents Of The University Of Michigan
Treatment of neurological disorders

EP3166688A4
(en)

2014-07-08
2017-12-20
New York University
Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy

LT3169706T
(en)

2014-07-11
2020-03-25
Genmab A/S
Antibodies binding axl

US11229713B2
(en)

2014-11-25
2022-01-25
Bristol-Myers Squibb Company
Methods and compositions for 18F-radiolabeling of biologics

DK3277725T3
(en)

2015-03-30
2021-01-11
Regeneron Pharma

Constant heavy chain regions with reduced binding to FC gamma receptors

WO2017009258A1
(en)

2015-07-10
2017-01-19
Genmab A/S
Axl-specific antibody-drug conjugates for cancer treatment

GB201512215D0
(en)

2015-07-13
2015-08-19
Lundbeck & Co As H
Agents,uses and methods

JO3711B1
(en)

2015-07-13
2021-01-31
H Lundbeck As
Antibodies specific for hyperphosphorylated tau and methods of use thereof

WO2017027685A2
(en)

2015-08-13
2017-02-16
New York University
Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy

US10358503B2
(en)

2015-08-13
2019-07-23
New York University
Antibody-based molecules selective for the {P}Ser404 epitope of Tau and their uses in the diagnosis and treatment of tauopathy

LT3458111T
(en)

2016-05-19
2021-05-25
Bristol-Myers Squibb Company
Pet-imaging immunomodulators

US10994033B2
(en)

2016-06-01
2021-05-04
Bristol-Myers Squibb Company
Imaging methods using 18F-radiolabeled biologics

HUE053679T2
(en)

2016-07-12
2021-07-28
H Lundbeck As
Antibodies specific for hyperphosphorylated tau and methods of use thereof

BR112019008702A2
(en)

2016-11-01
2019-07-16
Genmab B.V.

polypeptide, method of decreasing a polypeptide effector function, composition, method of treatment, kit of parts, and use of a polypeptide or composition.

EP3555127A1
(en)

2016-12-16
2019-10-23
H. Lundbeck A/S
Agents, uses and methods

EP3565836A1
(en)

2017-01-04
2019-11-13
H. Lundbeck A/S
Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases

US10894833B2
(en)

2017-07-20
2021-01-19
H. Lundbeck A/S
Agents, uses and methods for treatment

EP3743440A1
(en)

2018-01-24
2020-12-02
Genmab B.V.
Polypeptide variants and uses thereof

EP3820900A1
(en)

2018-07-13
2021-05-19
Genmab A/S
Variants of cd38 antibody and uses thereof

EP3958908A1
(en)

2019-04-24
2022-03-02
Heidelberg Pharma Research GmbH
Amatoxin antibody-drug conjugates and uses thereof

CN116003604A
(en)

2020-01-10
2023-04-25
科凌生物医疗有限公司
Epithelial cadherin-specific antibodies

EP3909601A1
(en)

2020-05-11
2021-11-17
LeukoCom GmbH
A novel antibody binding specifically to human ceacam1/3/5 and use thereof

Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4460561A
(en)

*

1980-03-03
1984-07-17

Goldenberg M David

Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers

US4460559A
(en)

*

1980-03-03
1984-07-17

Goldenberg Milton David

Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers

US4500508A
(en)

*

1983-05-03
1985-02-19

The United States Of America As Represented By The United States Department Of Energy

Radionuclide labeled lymphocytes for therapeutic use

Family Cites Families (16)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US3683066A
(en)

*

1969-01-14
1972-08-08
Ivan Ascanio
Technetium 99m colloidal composition

US3723612A
(en)

*

1969-08-08
1973-03-27
Inst Biofiziki
Stabilizer for radioactive colloidal solutions

GB1535847A
(en)

*

1976-03-19
1978-12-13
Radiochemical Centre Ltd
Technetium-99m labelled tin colloid for body scanning

US4070493A
(en)

*

1977-03-16
1978-01-24
Merck & Co., Inc.
Diagnostic kit

US4448200A
(en)

*

1978-03-27
1984-05-15
University Of Southern California
System and method for dynamic background subtraction

US4323546A
(en)

*

1978-05-22
1982-04-06
Nuc Med Inc.
Method and composition for cancer detection in humans

US4311688A
(en)

*

1979-10-29
1982-01-19
Serono Laboratories Inc.
Composition and method for cancer detection in humans

WO1981002522A1
(en)

*

1980-03-03
1981-09-17
M Goldenberg
Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers

US4444744A
(en)

*

1980-03-03
1984-04-24
Goldenberg Milton David
Tumor localization and therapy with labeled antibodies to cell surface antigens

DE3129906C3
(en)

*

1981-07-24
1996-12-19
Schering Ag

Paramagnetic complex salts, their preparation and agents for use in NMR diagnostics

US4454106A
(en)

*

1982-06-07
1984-06-12
Gansow Otto A
Use of metal chelate conjugated monoclonal antibodies

US4472509A
(en)

*

1982-06-07
1984-09-18
Gansow Otto A
Metal chelate conjugated monoclonal antibodies

US4443427A
(en)

*

1982-06-21
1984-04-17
Sidney Farber Cancer Institute, Inc.
Monoclonal antibody

ATE61000T1
(en)

*

1983-07-29
1991-03-15
Milton David Goldenberg

METHODS TO INCREASE TARGET SPECIFICITY IN ANTIBODY DETERMINATIONS AND REMOVE NON-TARGET-SPECIFIC DIAGNOSTIC AND THERAPEUTIC FACTORS.

FR2550449B1
(en)

*

1983-08-12
1986-01-31
Commissariat Energie Atomique

SPECIFIC ORGAN OR PATHOLOGY RELAXATION AGENTS FOR USE IN MODIFYING CONTRASTS IN MEDICAL IMAGING BY NUCLEAR MAGNETIC RESONANCE

CA1242643A
(en)

*

1983-08-12
1988-10-04
Eric T. Fossel
Nmr imaging utilizing chemical shift reagents

1985

1985-07-05
US
US06/751,877
patent/US4735210A/en
not_active
Expired – Fee Related

1986

1986-06-25
CA
CA000512351A
patent/CA1271522A/en
not_active
Expired – Fee Related

1986-07-03
AU
AU59728/86A
patent/AU589428B2/en
not_active
Ceased

1986-07-04
ZA
ZA864987A
patent/ZA864987B/en
unknown

1986-07-04
JP
JP61158626A
patent/JPH07116060B2/en
not_active
Expired – Lifetime

1986-07-04
IL
IL79333A
patent/IL79333A/en
not_active
IP Right Cessation

1986-07-07
EP
EP86305247A
patent/EP0208531B1/en
not_active
Expired – Lifetime

1986-07-07
DE
DE3650296T
patent/DE3650296T2/en
not_active
Expired – Fee Related

1986-07-07
AT
AT86305247T
patent/ATE120965T1/en
not_active
IP Right Cessation

1989

1989-05-18
AU
AU34959/89A
patent/AU619291B2/en
not_active
Ceased

Patent Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4460561A
(en)

*

1980-03-03
1984-07-17
Goldenberg M David
Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers

US4460559A
(en)

*

1980-03-03
1984-07-17
Goldenberg Milton David
Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers

US4500508A
(en)

*

1983-05-03
1985-02-19
The United States Of America As Represented By The United States Department Of Energy
Radionuclide labeled lymphocytes for therapeutic use

Also Published As

Publication number
Publication date

JPS6242935A
(en)

1987-02-24

CA1271522A
(en)

1990-07-10

JPH07116060B2
(en)

1995-12-13

AU3495989A
(en)

1989-09-14

DE3650296T2
(en)

1995-11-16

AU589428B2
(en)

1989-10-12

EP0208531B1
(en)

1995-04-12

IL79333A0
(en)

1986-10-31

ZA864987B
(en)

1988-03-30

US4735210A
(en)

1988-04-05

DE3650296D1
(en)

1995-05-18

ATE120965T1
(en)

1995-04-15

EP0208531A2
(en)

1987-01-14

AU5972886A
(en)

1987-01-08

EP0208531A3
(en)

1988-09-28

IL79333A
(en)

1992-09-06

Similar Documents

Publication
Publication Date
Title

AU619291B2
(en)

1992-01-23

Lymphographic imaging method and kit

US5101827A
(en)

1992-04-07

Lymphographic and organ imaging method and kit

EP1384488B1
(en)

2009-09-02

Method and kit for imaging organs and tissues, using labelled antibodies

AU613318B2
(en)

1991-08-01

Affinity enhancement system

WO1987000756A1
(en)

1987-02-12

Agents for use in tumour diagnosis, imaging, localization or treatment

Paganelli et al.

1994

Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99m Tc] PnAO-biotin

CA1244760A
(en)

1988-11-15

Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles

Fawwaz et al.

1985

Immunoreactivity and biodistribution of indium-111-labeled monoclonal antibody to a human high molecular weight-melanoma associated antigen

Kornguth et al.

1987

Magnetic resonance imaging of gadolinium-labeled monoclonal antibody polymers directed at human T lymphocytes implanted in canine brain

CA1323563C
(en)

1993-10-26

Lymphographic imaging method and kit

Koizumi et al.

1988

Immunoscintigraphy and pharmacokinetics of indium‐111‐labeled ZME‐018 monoclonal antibody in patients with malignant melanoma

EP0090025A4
(en)

1984-01-12

Specific mammary gland labelling.

Philpott et al.

1994

Immunoscintigraphy with a new indium-111-labeled monoclonal antibody (MAb 1A3) in patients with colorectal cancer

Springolo et al.

1989

The use of a monoclonal antibody against α‐fetoprotein for the radioimmunodetection of hepatocellular carcinoma

Curtet et al.

1989

Magnetic resonance imaging using NMR contrast agent gadolinium labeled monoclonal antibodies, Gd-DTPA-Mab 73.3 and 19.9 directed against CRC human tumor and Gd-DTPA-Mab OC 125 directed against human ovarian tumor

Perkins et al.

1988

Immunoscintigraphy and immunotherapy 1988 Report of the 3rd IRIST Meeting, Frankfurt/Main, March 1988

Roselli et al.

1989

Biodistribution of monoclonal antibody in patients with metastatic colorectal cancer: In vivo comparison of 111In vs 125I-B72. 3 IgG

Britton et al.

1991

Radioimmunoscintigraphy

Yemul et al.

1991

Tumor localization in nude mice bearing human breast carcinoma xenografts using 111In-DTPA conjugates of monoclonal antibodies

Legal Events

Date
Code
Title
Description

2000-02-10
MK14
Patent ceased section 143(a) (annual fees not paid) or expired

Download PDF in English